Gastrodia elata active ingredient ZTM100 and application thereof

Abstract

The invention provides a pedicel and inflorescence extract ZTM100 of Gastrodia elata Blume, a preparation method of the pedicel and inflorescence extract ZTM100 and application of the pedicel and inflorescence extract ZTM100 in the technical field of cosmetics and medicines. Belongs to the technical field of cosmetics and medicines. The ZTM100 (100 [mu] g / mL) provided by the invention can significantly improve the expression quantity of human dermal fibroblast elastin gene Elastin under UVA radiation, and does not show obvious cytotoxicity to human fibroblasts in a concentration range of 800 [mu] g / mL. The ZTM100 can be used for preparing medicines or cosmetics for resisting skin aging caused by UVA, reducing scar formation, repairing skin injury and repairing wounds.

Description

Technical Field

[0001] This invention belongs to the field of cosmetics and pharmaceutical technology, specifically relating to the field of plant cosmetics and plant medicines, and more specifically, relating to ZTM100, an active ingredient extracted from the flower stalk and inflorescence of Gastrodia elata, compositions containing it, their preparation methods, and their application in the preparation of drugs or cosmetics that combat UVA-induced skin aging, reduce scar formation, repair skin damage, repair wounds, and promote elastin gene expression and synthesis. Background Technology

[0002] The skin is the body's main protective barrier, composed of the epidermis, dermis, and subcutaneous tissue. The dermis is mainly composed of fibroblasts and the extracellular matrix (ECM) they produce, with elastin accounting for approximately 0.6%–7.9% of the ECM [Gardeazabal L., Izeta A. Elastin and collagen fibres in cutaneous wound healing. Experimental Dermatology, 2024, 33 (3), e15052]. In ultraviolet (UV) radiation, long-wave UVA (320–400 nm) can penetrate deep into the dermis, triggering a series of pathological events, including excessive generation of reactive oxygen species (ROS), activation of matrix metalloproteinases (MMPs), and degradation of ECM components such as collagen and elastin. These processes ultimately lead to decreased skin elasticity, wrinkle formation, and impaired barrier function, necessitating effective preventative strategies [Fu B., WanY., Ma X., Chang Z., Yang X., Liu X., Wu H., Cheng S., Du M. Salmon leathercollagen peptide alleviates UVA-induced photoaging via Nrf2 / Keap1 pathway by enhancing antioxidant defense and preserving skin elasticity. FoodBioscience, 2025, 72, 107494]. Elastin is abundant in normal skin and common scars, but rarely found in hypertrophic scars or keloids [Labadie JG, Dasgeb B., Phillips TJ, Arndt K. A., What Are Scars? In Procedures in Cosmetic Dermatology: Scar Management (Second Edition), Labadie, JG; Alam, M.; Dover, JS, Eds. Elsevier:2025; pp 1-10]. The soft tissue of scars treated with pressure therapy showed significant improvement in flexibility, and the transcriptional level and expression of elastin were increased [Zhang Yixin, Chai Jun. Mechanism and clinical application of pressure therapy for scars. Chinese Journal of Burns and Wound Repair, 2025, 41 (4), 316-324].Therefore, promoting the expression of elastin genes and the synthesis of elastin is beneficial for combating skin aging caused by UVA, for repairing skin damage, and for reducing scar formation. Summary of the Invention

[0003] This invention is based on the significant activity and function of ZTM100, an active ingredient from the extract of Gastrodia elata flower stalks and inflorescences, in promoting the expression of elastin genes and the synthesis of elastin. It possesses the activity and function of combating UVA-induced skin aging, repairing skin damage, reducing scar formation, and repairing wounds. The aim is to provide ZTM100, a composition containing it, its preparation method, and its application in the preparation of cosmetics and pharmaceuticals. Specifically, its application in the preparation of anti-skin aging drugs, drugs for reducing scar formation, and drugs for repairing skin damage, repairing wounds, and promoting elastin gene expression and synthesis. It also applies to the preparation of cosmetics for combating UVA-induced skin aging, cosmetics for repairing skin damage, and cosmetics for reducing scar formation, repairing wounds, and promoting elastin gene expression and synthesis. A novel preparation method for ZTM100, an active ingredient from the extract of Gastrodia elata flower stalks and inflorescences, is also provided.

[0004] The purpose of this invention is to provide an active ingredient ZTM100 from the extracts of Gastrodia elata flower stalks and inflorescences.

[0005] To achieve the above-mentioned objectives of the present invention, the present invention provides the following technical solution:

[0006] The active extract component ZTM100 from Gastrodia elata is prepared by the following method:

[0007] After seed collection, the dried flower stalks and inflorescences of Gastrodia elata were crushed and extracted three times with 90% ethanol at 70 °C for 3 h each time. The extracts were combined and concentrated at 60 °C using a rotary evaporator to obtain a crude extract. The crude extract was then mixed with distilled water to form a suspension, filtered, and the filtrate was subjected to column chromatography using AB-8 macroporous adsorption resin at a flow rate of 1 column volume / h with distilled water. The eluent was collected, and the solvent was recovered to obtain the eluent fraction. This eluent fraction was then mixed with distilled water to form a suspension, and subjected to column chromatography using HPD600 macroporous adsorption resin at a flow rate of 1 BV / h with distilled water. The eluent was collected, and the solvent was recovered to obtain the eluent fraction ZTM100.

[0008] The application of the Gastrodia elata active ingredient ZTM100 in drugs for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

[0009] The application of the active ingredient ZTM100 from Gastrodia elata in the preparation of cosmetics for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

[0010] A method for preparing the active ingredient ZTM100 from Gastrodia elata, comprising the following steps:

[0011] After seed collection, the dried flower stalks and inflorescences of Gastrodia elata were crushed and extracted three times with 90% ethanol at 70 °C for 3 h each time. The extracts were combined and concentrated at 60 °C using a rotary evaporator to obtain a crude extract. The crude extract was then mixed with distilled water to form a suspension, filtered, and the filtrate was subjected to column chromatography using AB-8 macroporous adsorption resin at a flow rate of 1 column volume / h with distilled water. The eluent was collected, and the solvent was recovered to obtain the eluent fraction. This eluent fraction was then mixed with distilled water to form a suspension, and subjected to column chromatography using HPD600 macroporous adsorption resin at a flow rate of 1 BV / h with distilled water. The eluent was collected, and the solvent was recovered to obtain the eluent fraction ZTM100.

[0012] The pharmaceutical composition comprises the aforementioned active ingredient ZTM100 from Gastrodia elata and a pharmaceutically acceptable carrier.

[0013] The pharmaceutical composition is used in the preparation of drugs for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

[0014] The method for preparing the pharmaceutical composition includes the following steps: first, obtaining the active ingredient ZTM100 of Gastrodia elata by the method for preparing ZTM100, and then adding a pharmaceutically acceptable carrier.

[0015] The cosmetic uses the aforementioned Gastrodia elata active ingredient ZTM100 as the active ingredient, along with conventional cosmetic excipients.

[0016] The method for preparing the cosmetic comprises the following steps: first, obtaining the active ingredient ZTM100 from Gastrodia elata using the method for preparing ZTM100, and then adding commonly used cosmetic excipients.

[0017] The application of the active ingredient ZTM100 from Gastrodia elata in the preparation of drugs or cosmetics that promote elastin gene expression and synthesis.

[0018] The application of the active ingredient ZTM100 from Gastrodia elata in the preparation of drugs or cosmetics for wound repair.

[0019] In this invention, when the extract ZTM100 or its composition is used to prepare a drug, the content of the extract or its composition in the drug is preferably 0.1% to 99%; in the drug composition, the content of any one or any combination of the active ingredient extracts is preferably 0.5% to 90%. The drug composition of this invention is preferably used in the form of a dose per unit body weight. In this invention, the prepared drug is preferably administered orally or topically. The drug preparations include topical ointments, tablets, capsules, pills, drops, etc., including but not limited to the above-mentioned preparations.

[0020] In this invention, when extract ZTM100 is used to prepare cosmetics, the formulation of the cosmetics is not limited and can be prepared using conventional cosmetic preparation methods.

[0021] Compared with the prior art, the present invention has the following advantages:

[0022] 1. ZTM100, an extract of Gastrodia elata flower stalks and inflorescences, can significantly promote the expression of elastin genes in human dermal fibroblasts under UVA radiation.

[0023] 2. The extract ZTM100 from the flower stalks and inflorescences of Gastrodia elata showed no toxicity to human dermal fibroblasts at a concentration range of 800 μg / mL.

[0024] 3. This invention provides a method for preparing ZTM100, an extract of Gastrodia elata flower stalks and inflorescences. The raw materials are readily available, the process is simple, the operation is convenient, and the cost is low.

[0025] 4. ZTM100, an extract from the flower stalks and inflorescences of Gastrodia elata, exhibits significant activity in promoting elastin gene expression and elastin synthesis, and can be used to prepare drugs or cosmetics that promote elastin gene expression and synthesis. It also possesses pharmacological activities and functions in combating UVA-induced skin aging, repairing skin damage, reducing scar formation, and repairing wounds, and can be used to prepare drugs or cosmetics with similar functions and effects. Attached Figure Description

[0026] Figure 1 ZTM100 did not show significant cytotoxicity against human dermal fibroblasts at a concentration range of 800 μg / mL. Detailed Implementation

[0027] The following embodiments of the present invention will further illustrate the substantive content of the present invention, but are not intended to limit the present invention.

[0028] Example 1

[0029] Preparation of ZTM100 extract from the flower stalks and inflorescences of Gastrodia elata Blume:

[0030] After the seeds were collected, the dried flower stalks and inflorescences of Gastrodia elata (10.0 kg) were crushed and extracted three times with 90% ethanol (80 L) at 70 °C for 3 h each time. The extracts were combined and concentrated using a rotary evaporator at 60 °C to obtain crude extract (0.9 kg).

[0031] Take 3 g of crude extract, add distilled water (30 mL) to prepare a suspension, filter, and perform column chromatography on AB-8 macroporous adsorption resin (30 g) at a flow rate of 1 column volume (BV) / h with distilled water. Collect the eluent, recover the solvent from the eluent, and obtain the eluent fraction (907.5 mg). Take 400 mg of this eluent fraction, add distilled water (4 mL) to prepare a suspension, and perform column chromatography on HPD600 macroporous adsorption resin (30 g) at a flow rate of 1 BV / h with distilled water. Collect the eluent, recover the solvent from the eluent, and obtain the eluent fraction (258.5 mg), which is ZTM100.

[0032] Example 2

[0033] Activity assay of ZTM100 extract from Gastrodia elata flower stalks and inflorescences:

[0034] 1. Cell

[0035] The cells used in this test were human dermal fibroblasts, batch number: Fb230131, provided by Guangdong Boxi Shaanxi Branch.

[0036] 2. Main reagents

[0037] DMEM culture medium (Gibco), fetal bovine serum (Lanzhou Rongye), PBS (Solepro), MTT (Sigma), DMSO (Sigma), AG RNAex Pro Reagent (Aikerui Biotechnology), reverse transcription kit (Aikerui Biotechnology), fluorescent dye (Aikerui Biotechnology), TGF-β1 (Peprotech).

[0038] 3. Main Equipment

[0039] CO2 incubator (Thermo, 150I), ultra-clean workbench (Sujing Antai, SW-CJ-2F), microplate reader (BioTek, Epoch), UVA irradiator (Philips), inverted microscope (Olympus, CKX53), and real-time PCR instrument (Roche, Lightcycler 480 II).

[0040] 4. Cytotoxicity assay based on human dermal fibroblasts

[0041] 4.1 Cell viability testing methods

[0042] 1) Cell seeding: After cell resuscitation, when the cell plating rate reaches about 50%~60%, seed the cells into 96-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).

[0043] 2) Experimental Groups: The experiment included a zeroing group, a solvent control group, a positive control group, and a sample group. In the sample group, each sample had 8 concentration gradients, and each concentration gradient had 3 replicate wells.

[0044] 3) Solution preparation: Prepare working solutions of the ZTM100 sample to be tested with concentrations of 6.25 μg / mL, 12.5 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL, 200 μg / mL, 400 μg / mL and 800 μg / mL.

[0045] 4) Drug administration: Drug administration was performed when the cell seeding rate in the 96-well plate reached 50%–60%. For the solvent control group, 200 μL of culture medium was added to each well; for the positive control group, 200 μL of culture medium containing 10% DMSO was added to each well; for the sample group, 200 μL of culture medium containing the corresponding concentration of the sample was added to each well; for the zeroing group, no cells were seeded, only 200 μL of cell culture medium was added. After drug administration, the 96-well plate was placed in a CO2 incubator (37 ℃, 5% CO2) and incubated for 24 h.

[0046] 5) Detection: After culturing cells for 24 h, discard the supernatant, add MTT working solution (0.5 mg / mL), and incubate at 37 ℃ in the dark for 4 h. After incubation, discard the supernatant, add 150 μL DMSO to each well, and read the OD value at 490 nm.

[0047] 6) Calculation of relative cell viability: According to the formula, relative cell viability (%) = [(sample well OD − zeroing well OD) / (solvent control well OD − zeroing well OD)] × 100%.

[0048] 4.2 Cell morphology testing methods

[0049] 1) Cell seeding: After cell resuscitation, when the cell seeding rate reaches about 50%~60%, seed the cells into 24-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).

[0050] 2) Experimental Groups: The experiment included a solvent control group and a sample group. Within the sample group, five concentration gradients were set up (50 μg / mL, 100 μg / mL, 200 μg / mL, 400 μg / mL, and 800 μg / mL).

[0051] 3) Drug administration: Drug administration was performed when the cell deposition rate in the 24-well plate reached 50%–60%. 1 mL of culture medium was added to each well of the solvent control group; 1 mL of culture medium containing the corresponding concentration of the test sample was added to each well of the sample group. After drug administration, the 24-well plate was placed in a CO2 incubator (37 °C, 5% CO2) and incubated for 24 h.

[0052] 4) Take photos: After incubation, discard the supernatant and take photos under an inverted microscope.

[0053] 4.3 Test Results

[0054] Based on MTT (Table 1) and morphological results ( Figure 1 Based on human fibroblasts, ZTM100 did not show significant cytotoxicity in the concentration range of 800 μg / mL.

[0055] Table 1. MTT assay results of ZTM100 on human dermal fibroblasts

[0056]

[0057] 5. Gene expression level assay based on fibroblasts

[0058] 5.1 Test Method

[0059] 1) Cell seeding: After cell resuscitation, when the cell plating rate reaches about 60%, seed the cells into 6-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).

[0060] 2) Solution preparation: Prepare working solutions for the test substances according to the test groups.

[0061] 3) Drug administration: According to the test groups, when the cell deposition rate in the 6-well plate reached 30%~50%, drug administration was performed in groups, with 3 replicates per group. 2 mL of culture medium was added to each well of the blank control group and negative control group, 2 mL of culture medium containing the corresponding concentration of TGF-β1 was added to each well of the positive control group, and 2 mL of culture medium containing the corresponding concentration of the test sample was added to each well of the sample group. After drug administration, the 6-well plate was incubated in a CO2 incubator (37 °C, 5% CO2) for 24 h.

[0062] 4) UVA irradiation: According to the test grouping, all groups except the blank control group were subjected to UVA irradiation with an irradiation dose of 30 J / cm². 2After irradiation, the samples were placed in an incubator (37 °C, 5% CO2) and cultured for another 24 h.

[0063] 5) Cell collection: After incubation, aspirate the old solution, wash twice with PBS, add 1 mL of AG RNAex ProReagent to each well, lyse the cells by pipetting, and collect the sample.

[0064] 6) Gene expression detection: RNA was extracted, reverse transcribed into cDNA, and then detected by real-time quantitative PCR using 2... -△△CT The method is used to calculate the results.

[0065] 7) Calculation of upward adjustment rate:

[0066] Upregulation rate (%) = [(Sample group − Blank control group) / Blank control group] × 100%

[0067] 8) Statistical Analysis of Results: GraphPad Prism Program software was used for plotting, and the results are expressed as Mean ± SD. t-tests were used for comparisons between groups. All statistical analyses were two-tailed. P < 0.05 was considered statistically significant, and P < 0.01 was considered highly statistically significant.

[0068] 5.2 Results of Elastin Gene Expression Test

[0069] The test results are shown in Table 2. Compared with the blank control (BC) group, the expression level of Elastin gene in the negative control (NC) group was significantly downregulated, indicating that the stimulation conditions of this test were effective. Compared with the NC group, the expression level of Elastin gene in the positive control (PC) group was significantly upregulated, indicating that the positive control of this test was effective. Compared with the NC group, the expression level of Elastin gene in sample ZTM100 (100 μg / mL) was significantly upregulated, with an upregulation rate of 81.94%.

[0070] Table 2. Results of Elastin gene detection

[0071]

[0072] Note: Use 2 -△△CT When calculating the results using the method and performing statistical analysis using the t-test, the significance level compared to the BC group was [missing information]. # This means that P < 0.05 indicates that... # P < 0.01 indicates that ## Compared with the NC group, significance is indicated by *, P < 0.05 is indicated by *, and P < 0.01 is indicated by **.

[0073] Example 3:

[0074] Add the excipients to the extract of Gastrodia elata flower stalk and inflorescence ZTM100 at a weight ratio of 1:1 or 1:2, and then granulate and compress the mixture into tablets.

[0075] Example 4:

[0076] Tablets: Gastrodia elata flower stalk and inflorescence extract ZTM100 10mg, lactose 180mg, starch 55mg, magnesium stearate 5mg; Preparation method: Gastrodia elata flower stalk and inflorescence extract ZTM100, lactose and starch are mixed and moistened with water. The moistened mixture is sieved and dried, then sieved again. Magnesium stearate is added, and the mixture is then compressed into tablets. Each tablet weighs 250 mg and contains 10 mg of the compound.

[0077] Example 5:

[0078] Extract ZTM100 from the flower stalks and inflorescences of Gastrodia elata was prepared into capsules using conventional capsule formulation methods.

[0079] Example 6:

[0080] Capsules: Gastrodia elata flower stalk and inflorescence extract ZTM100 10 mg, lactose 187 mg, magnesium stearate 3 mg;

[0081] Preparation method: Mix the extracts of Gastrodia elata flower stalks and inflorescences ZTM100 with the adjuvants, sieve, mix evenly, and fill the resulting mixture into hard gelatin capsules, each capsule weighing 200 mg and containing 10 mg of active ingredients.

[0082] Example 7:

[0083] Topical ointment: Melt the base ingredients (such as beeswax and coconut oil) by heating in a water bath, add the extract of Gastrodia elata flower stalk and inflorescence ZTM100 and stir well. After cooling, put it into a sterilized sealed container and refrigerate.

[0084] Example 8:

[0085] Cream formulation (W%) containing ZTM100 extract of Gastrodia elata flower stalks and inflorescences:

[0086] Gastrodia elata flower stalk and inflorescence extract ZTM100 0.03

[0087] Stearic acid 8.0

[0088] C16 alcohol 2.0

[0089] Self-emulsifying monoglyceride 2.0

[0090] Hydrogenated lanolin 2.0

[0091] Liquid paraffin 12.0

[0092] Glycerin 7.0

[0093] Emulsifier 1.5

[0094] Preservative 0.2

[0095] Fragrance 0.2

[0096] Add deionized water to 100

[0097] The cosmetic product of the above-described formula of the present invention is prepared using conventional methods for manufacturing cosmetics.

[0098] Example 9:

[0099] Emulsion formulation (W%) containing ZTM100 extract of Gastrodia elata flower stalks and inflorescences:

[0100] Gastrodia elata flower stalk and inflorescence extract ZTM100 0.03

[0101] Stearic acid 1.4

[0102] Cetyl alcohol 0.1

[0103] 2-Ethyl alcohol cetyl stearate 1.8

[0104] Isopropyl myristate 0.2

[0105] 2-Hexyl-1-decyl alcohol 1.0

[0106] Liquid paraffin 7.5

[0107] Glycerin 3.0

[0108] Propylene glycol 8.0

[0109] Triethanolamine 1.0

[0110] Carboxyvinyl polymer 0.35

[0111] Arlacel 165 2.0

[0112] Preservative 0.2

[0113] Fragrance 0.2

[0114] Add deionized water to 100

[0115] The cosmetic product of the above-described formula of the present invention is prepared using conventional methods for manufacturing cosmetics.

[0116] Example 10

[0117] A facial cleanser containing ZTM100 extract of Gastrodia elata flower stalks and inflorescences.

[0118] 1. Materials

[0119] The extract ZTM100 of Gastrodia elata flower stalks and inflorescences obtained by the same method as in Example 1 uses cosmetic-grade or food-grade raw materials.

[0120] 2. Formula

[0121] Gastrodia elata flower stalk and inflorescence extract ZTM100 0.5 g, glycerin 3.0 g, butylene glycol 3.0 g, propylene glycol 0.6 g, sodium EDTA 0.1 g, guar gum 0.3 g, zinc dioxide 2.0 g, C12-15 benzoate 4.0 g, C12-20 alkyl glucoside 3.0 g, C14-22 alcohol 0.5 g, cetearyl alcohol 1.2 g, parabens 0.2 g, sodium stearate 0.3 g, polydimethylsiloxane alcohol 0.5 g, polysorbate 0.2 g, deionized water 60 g.

[0122] 3. Preparation process

[0123] Weigh out the required amount of Gastrodia elata flower stalk and inflorescence extract ZTM100 and dissolve it completely in purified water. Take glycerin, butylene glycol, propylene glycol, sodium EDTA, guar gum, zinc dioxide, sodium stearate, C12-15 benzoate, C12-20 alkyl glucoside, C14-22 alcohol, and cetearyl alcohol, and mix them with purified water. Take parabens, polydimethylsiloxane alcohol, and polysorbate, and mix them with purified water. Combine the prepared solutions, stir thoroughly, and bottle to obtain the final product.

Claims

1. The active ingredient ZTM100 from Gastrodia elata, characterized in that: It is prepared by the following method: After seed collection, the dried flower stalks and inflorescences of Gastrodia elata were pulverized and extracted three times with 90% ethanol at 70 °C for 3 hours each time. The extracts were combined and concentrated using a rotary evaporator at 60 °C to obtain a crude extract. The crude extract was then mixed with distilled water to form a suspension, filtered, and the filtrate was subjected to column chromatography using AB-8 macroporous adsorption resin at a flow rate of 1 column volume / h, eluted with distilled water, and the eluent was collected. After solvent recovery, the eluent fraction was obtained. This eluent fraction was then mixed with distilled water to form a suspension, and subjected to column chromatography using HPD600 macroporous adsorption resin at a flow rate of 1 BV / h, eluted with distilled water, and the eluent was collected. After solvent recovery, the eluent fraction ZTM100 was obtained.

2. The application of the active ingredient ZTM100 of Gastrodia elata as described in claim 1 in the preparation of a drug for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

3. The application of the active ingredient ZTM100 of Gastrodia elata as described in claim 1 in the preparation of cosmetics for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

4. A method for preparing the active ingredient ZTM100 from Gastrodia elata, characterized in that, The method includes the following steps: After seed collection, the dried flower stalks and inflorescences of Gastrodia elata were pulverized and extracted three times with 90% ethanol at 70 °C for 3 hours each time. The extracts were combined and concentrated using a rotary evaporator at 60 °C to obtain a crude extract. The crude extract was then mixed with distilled water to form a suspension, filtered, and the filtrate was subjected to column chromatography using AB-8 macroporous adsorption resin at a flow rate of 1 column volume / h, eluted with distilled water, and the eluent was collected. After solvent recovery, the eluent fraction was obtained. This eluent fraction was then mixed with distilled water to form a suspension, and subjected to column chromatography using HPD600 macroporous adsorption resin at a flow rate of 1 BV / h, eluted with distilled water, and the eluent was collected. After solvent recovery, the eluent fraction ZTM100 was obtained.

5. A pharmaceutical composition comprising the active ingredient ZTM100 of Gastrodia elata as described in claim 1 and a pharmaceutically acceptable carrier.

6. The use of the pharmaceutical composition of claim 5 in the preparation of a medicament for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

7. The use of the active ingredient ZTM100 from Gastrodia elata according to claim 1 in the preparation of drugs or cosmetics for wound repair.

8. A cosmetic product, comprising the active ingredient ZTM100 of Gastrodia elata as described in claim 1 as an effective ingredient, plus conventional cosmetic excipients.

9. The method for preparing the cosmetic according to claim 8, characterized in that, The method includes the following steps: first, the active ingredient ZTM100 of Gastrodia elata is obtained by the preparation method described in claim 4, and then commonly used cosmetic excipients are added.

10. The use of the active ingredient ZTM100 from Gastrodia elata according to claim 1 in the preparation of drugs or cosmetics that promote elastin gene expression and synthesis.

Images